CN105861441B - 一种来源于人肝细胞癌癌旁组织的肝癌细胞系stl-c1及其建系方法 - Google Patents
一种来源于人肝细胞癌癌旁组织的肝癌细胞系stl-c1及其建系方法 Download PDFInfo
- Publication number
- CN105861441B CN105861441B CN201610202256.XA CN201610202256A CN105861441B CN 105861441 B CN105861441 B CN 105861441B CN 201610202256 A CN201610202256 A CN 201610202256A CN 105861441 B CN105861441 B CN 105861441B
- Authority
- CN
- China
- Prior art keywords
- liver cancer
- cell
- liver
- cancer
- cell lines
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 208000014018 liver neoplasm Diseases 0.000 title claims abstract description 89
- 201000007270 liver cancer Diseases 0.000 title claims abstract description 88
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 58
- 201000011510 cancer Diseases 0.000 title claims abstract description 40
- 206010073071 hepatocellular carcinoma Diseases 0.000 title abstract description 20
- 231100000844 hepatocellular carcinoma Toxicity 0.000 title abstract description 6
- 238000000034 method Methods 0.000 title description 21
- 238000011160 research Methods 0.000 claims abstract description 13
- 230000015572 biosynthetic process Effects 0.000 claims abstract description 9
- 206010027476 Metastases Diseases 0.000 claims abstract description 4
- 230000009401 metastasis Effects 0.000 claims abstract description 4
- 238000010171 animal model Methods 0.000 claims description 5
- 206010019695 Hepatic neoplasm Diseases 0.000 claims description 2
- 229940079593 drug Drugs 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims description 2
- 238000002474 experimental method Methods 0.000 abstract description 12
- 238000000338 in vitro Methods 0.000 abstract description 11
- 239000000463 material Substances 0.000 abstract description 6
- 206010073069 Hepatic cancer Diseases 0.000 abstract description 5
- 230000006399 behavior Effects 0.000 abstract description 4
- 238000010276 construction Methods 0.000 abstract description 4
- 238000001727 in vivo Methods 0.000 abstract description 3
- 230000007774 longterm Effects 0.000 abstract description 2
- 244000005700 microbiome Species 0.000 abstract description 2
- 210000004027 cell Anatomy 0.000 description 116
- 230000010412 perfusion Effects 0.000 description 19
- 210000001519 tissue Anatomy 0.000 description 19
- 210000004185 liver Anatomy 0.000 description 17
- 230000012010 growth Effects 0.000 description 16
- 239000007788 liquid Substances 0.000 description 16
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 15
- 239000000243 solution Substances 0.000 description 15
- 238000012546 transfer Methods 0.000 description 11
- 230000001464 adherent effect Effects 0.000 description 10
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 9
- 238000011081 inoculation Methods 0.000 description 9
- 238000011580 nude mouse model Methods 0.000 description 9
- 210000003240 portal vein Anatomy 0.000 description 9
- 102000029816 Collagenase Human genes 0.000 description 8
- 108060005980 Collagenase Proteins 0.000 description 8
- 229960002424 collagenase Drugs 0.000 description 8
- 239000012894 fetal calf serum Substances 0.000 description 8
- 210000000130 stem cell Anatomy 0.000 description 8
- 230000007246 mechanism Effects 0.000 description 7
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 241000699660 Mus musculus Species 0.000 description 6
- 239000007853 buffer solution Substances 0.000 description 6
- 108010019160 Pancreatin Proteins 0.000 description 5
- 210000000349 chromosome Anatomy 0.000 description 5
- 239000011248 coating agent Substances 0.000 description 5
- 238000000576 coating method Methods 0.000 description 5
- 230000029087 digestion Effects 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 229940055695 pancreatin Drugs 0.000 description 5
- 238000000926 separation method Methods 0.000 description 5
- 102000018651 Epithelial Cell Adhesion Molecule Human genes 0.000 description 4
- 108010066687 Epithelial Cell Adhesion Molecule Proteins 0.000 description 4
- 102100024785 Fibroblast growth factor 2 Human genes 0.000 description 4
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 210000004881 tumor cell Anatomy 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 206010027458 Metastases to lung Diseases 0.000 description 3
- 239000004677 Nylon Substances 0.000 description 3
- 208000007536 Thrombosis Diseases 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 230000010261 cell growth Effects 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 238000004140 cleaning Methods 0.000 description 3
- DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 3
- 239000012091 fetal bovine serum Substances 0.000 description 3
- 238000000684 flow cytometry Methods 0.000 description 3
- 230000003902 lesion Effects 0.000 description 3
- 229920001778 nylon Polymers 0.000 description 3
- 238000004321 preservation Methods 0.000 description 3
- 229910052711 selenium Inorganic materials 0.000 description 3
- 239000011669 selenium Substances 0.000 description 3
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 229930182555 Penicillin Natural products 0.000 description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
- 108010087230 Sincalide Proteins 0.000 description 2
- 102000002070 Transferrins Human genes 0.000 description 2
- 108010015865 Transferrins Proteins 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 238000010609 cell counting kit-8 assay Methods 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 208000019425 cirrhosis of liver Diseases 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- BVTBRVFYZUCAKH-UHFFFAOYSA-L disodium selenite Chemical class [Na+].[Na+].[O-][Se]([O-])=O BVTBRVFYZUCAKH-UHFFFAOYSA-L 0.000 description 2
- 239000003292 glue Substances 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 229960002897 heparin Drugs 0.000 description 2
- 229920000669 heparin Polymers 0.000 description 2
- 238000011065 in-situ storage Methods 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000000877 morphologic effect Effects 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 230000008520 organization Effects 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 229940049954 penicillin Drugs 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- 230000002980 postoperative effect Effects 0.000 description 2
- 230000003449 preventive effect Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 238000002271 resection Methods 0.000 description 2
- IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 description 2
- 235000015921 sodium selenite Nutrition 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 230000005740 tumor formation Effects 0.000 description 2
- 238000011729 BALB/c nude mouse Methods 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 101100191768 Caenorhabditis elegans pbs-4 gene Proteins 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 206010008909 Chronic Hepatitis Diseases 0.000 description 1
- 208000000419 Chronic Hepatitis B Diseases 0.000 description 1
- 208000024678 Complex chromosomal rearrangement Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 208000005189 Embolism Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 241001582888 Lobus Species 0.000 description 1
- 206010050017 Lung cancer metastatic Diseases 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 235000003140 Panax quinquefolius Nutrition 0.000 description 1
- 240000005373 Panax quinquefolius Species 0.000 description 1
- 241000270708 Testudinidae Species 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 239000003855 balanced salt solution Substances 0.000 description 1
- 230000004791 biological behavior Effects 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 230000003139 buffering effect Effects 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 239000012578 cell culture reagent Substances 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000002759 chromosomal effect Effects 0.000 description 1
- 230000007882 cirrhosis Effects 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 230000001332 colony forming effect Effects 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 239000003636 conditioned culture medium Substances 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 230000003328 fibroblastic effect Effects 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 239000012737 fresh medium Substances 0.000 description 1
- 210000001652 frontal lobe Anatomy 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 230000008676 import Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000004026 insulin derivative Substances 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000012577 media supplement Substances 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000009456 molecular mechanism Effects 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 210000001711 oxyntic cell Anatomy 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000000258 photobiological effect Effects 0.000 description 1
- 238000010837 poor prognosis Methods 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000004064 recycling Methods 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 239000013049 sediment Substances 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0693—Tumour cells; Cancer cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/05—Inorganic components
- C12N2500/10—Metals; Metal chelators
- C12N2500/20—Transition metals
- C12N2500/24—Iron; Fe chelators; Transferrin
- C12N2500/25—Insulin-transferrin; Insulin-transferrin-selenium
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/115—Basic fibroblast growth factor (bFGF, FGF-2)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2509/00—Methods for the dissociation of cells, e.g. specific use of enzymes
Abstract
Description
Claims (4)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610202256.XA CN105861441B (zh) | 2016-04-01 | 2016-04-01 | 一种来源于人肝细胞癌癌旁组织的肝癌细胞系stl-c1及其建系方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610202256.XA CN105861441B (zh) | 2016-04-01 | 2016-04-01 | 一种来源于人肝细胞癌癌旁组织的肝癌细胞系stl-c1及其建系方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN105861441A CN105861441A (zh) | 2016-08-17 |
CN105861441B true CN105861441B (zh) | 2018-06-12 |
Family
ID=56626724
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201610202256.XA Expired - Fee Related CN105861441B (zh) | 2016-04-01 | 2016-04-01 | 一种来源于人肝细胞癌癌旁组织的肝癌细胞系stl-c1及其建系方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN105861441B (zh) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108795851B (zh) * | 2017-04-27 | 2022-03-18 | 大连医科大学 | 一种人唾液腺腺样囊性癌癌相关成纤维细胞系caf-sa的建立方法及其应用 |
CN108967417B (zh) * | 2018-08-09 | 2019-05-10 | 爱克精医(北京)生物医药科技有限公司 | 一种肿瘤组织高活性储存运输液及其制备方法 |
CN109055302A (zh) * | 2018-08-28 | 2018-12-21 | 重庆医科大学附属第医院 | Hbv转基因小鼠原代肝细胞的分离、培养与鉴定的方法 |
CN111321119B (zh) * | 2020-03-18 | 2022-09-20 | 四川大学 | 一种适应规模化无血清贴壁培养的肝癌细胞系及其建立方法和应用 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101597591A (zh) * | 2008-06-06 | 2009-12-09 | 中国人民解放军第二军医大学东方肝胆外科医院 | 一种来源于人肝癌门静脉癌栓的肝癌细胞系及其建系方法 |
CN101693886A (zh) * | 2009-08-10 | 2010-04-14 | 北京肿瘤医院 | 一种肝癌细胞系及其应用 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW201031916A (en) * | 2009-02-20 | 2010-09-01 | Iner Aec Executive Yuan | A mammal dedicated cell lin |
-
2016
- 2016-04-01 CN CN201610202256.XA patent/CN105861441B/zh not_active Expired - Fee Related
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101597591A (zh) * | 2008-06-06 | 2009-12-09 | 中国人民解放军第二军医大学东方肝胆外科医院 | 一种来源于人肝癌门静脉癌栓的肝癌细胞系及其建系方法 |
CN101693886A (zh) * | 2009-08-10 | 2010-04-14 | 北京肿瘤医院 | 一种肝癌细胞系及其应用 |
Non-Patent Citations (1)
Title |
---|
肝癌肿瘤浸润淋巴细胞(TIL)体外扩增及特性研究;江珊珊等;《中国细胞生物学学报》;20141231;第36卷(第7期);摘要 * |
Also Published As
Publication number | Publication date |
---|---|
CN105861441A (zh) | 2016-08-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN105861441B (zh) | 一种来源于人肝细胞癌癌旁组织的肝癌细胞系stl-c1及其建系方法 | |
CN102465113B (zh) | 一种人肝癌细胞系及其应用 | |
CN107022521A (zh) | 壁蜕膜组织冻存、复苏及分离培养间充质干细胞的方法 | |
CN102250840B (zh) | 一种人胰腺癌细胞系及其应用 | |
CN104531620A (zh) | 肺癌干细胞条件3d培养方法 | |
CN102161980B (zh) | 用人间充质干细胞为滋养层培养诱导多能干细胞的方法 | |
CN104694476A (zh) | 一种人非小细胞肺癌细胞系及其建立方法和应用 | |
CN103881975B (zh) | 人前列腺癌细胞及其原代分离培养和传代培养方法与用途 | |
CN102719403B (zh) | 一种人胰腺腺鳞癌细胞系及其建立方法和应用 | |
CN101531996B (zh) | 源于成形组织的间充质干细胞的分离和纯化方法 | |
CN101993854B (zh) | 一种来源于肝转移灶的大肠癌细胞系cjf及其构建方法 | |
CN107177551B (zh) | 一种具有高成瘤能力的人肝内胆管癌细胞系及其应用 | |
CN104195109A (zh) | 一种人肺腺癌细胞系及其应用 | |
CN102181399B (zh) | 一种cd133高表达鼠肝肿瘤细胞系及制备方法 | |
CN102329775B (zh) | 一种对吉西他滨耐药的人胰腺癌细胞系及其应用 | |
CN104745530A (zh) | 一种人肝细胞癌细胞系及其建立方法和应用 | |
CN105062973B (zh) | 一株携带tp53突变的hpv阴性阴茎鳞癌细胞系及其用途 | |
CN104419660A (zh) | 制备自体造血干细胞的方法、试剂盒、干细胞及应用 | |
CN103013923A (zh) | 建立人卵巢癌动物模型的方法 | |
CN109355261A (zh) | 一种尿源性膀胱癌细胞培养基及尿源性膀胱癌细胞的体外培养方法 | |
CN104894052A (zh) | 基于三维细胞培养的3d细胞培养基及其建立遗传毒性检测体系的方法 | |
CN103911343A (zh) | 一种多器官转移人膀胱癌细胞 | |
CN101597591B (zh) | 一种来源于人肝癌门静脉癌栓的肝癌细胞系及其建系方法 | |
CN101824397B (zh) | 一种肝癌细胞系ehbc-512及其应用 | |
CN104894088A (zh) | 消化酶组合物及其应用、脐带上皮细胞的分离培养方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
CB03 | Change of inventor or designer information | ||
CB03 | Change of inventor or designer information |
Inventor after: Wang Hongyang Inventor after: Yan Hexin Inventor after: Wang Mingda Inventor after: Wu Han Inventor after: Fu Gongbo Inventor after: Zhou Xu Inventor after: Zeng Min Inventor after: Huang Weijian Inventor before: Wang Hongyang Inventor before: Yan Hexin Inventor before: Wang Mingda Inventor before: Wu Han Inventor before: Fu Gongbo Inventor before: Zhou Xu |
|
GR01 | Patent grant | ||
GR01 | Patent grant | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20180612 |